Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262172 | 0.89 | PDE7A (0.41) | PDE7APDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5607475 | 0.88 | ALDH1A1 (0.50) | PIK3CDALDH1A1HSD17B10RXFP1SMN1; SMN2 | |
| SCHEMBL5606786 | 0.87 | PIK3CD (0.45) | PDE4DPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL5606945 | 0.87 | PIK3CD (0.52) | PIK3CDALDH1A1HSD17B10RXFP1PIK3CG | |
| SCHEMBL5606274 | 0.86 | PIK3CD (0.44) | PIK3CDALDH1A1HSD17B10RXFP1SMN1; SMN2 | |
| SCHEMBL5606978 | 0.85 | PIK3CG (0.51) | PDE4DPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL5607282 | 0.83 | PIK3CD (0.41) | PDE4DPIK3CDALDH1A1HSD17B10RXFP1 | |
| SCHEMBL5608379 | 0.82 | ALDH1A1 (0.48) | PIK3CDALDH1A1HSD17B10RXFP1SMN1; SMN2 | |
| SCHEMBL5608415 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL5607273 | 0.82 | PIK3CD (0.43) | PDE4DPIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | claimed |
| EP-3102238-A1 | THERAPIES FOR TREATING CANCERS | Gilead Sciences, Inc. (US) | 2016-12-14 | — | — | EP | claimed |
| WO-2015109286-A1 | THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2015-07-23 | — | — | WO | claimed |
| EP-2579878-A1 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS | Gilead Calistoga LLC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210030793-A1 | METHODS AND COMPOSITIONS FOR TREATING CD33+ CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-3169366-A1 | COMBINATIONS FOR TREATING CANCERS | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3102238-A1 | THERAPIES FOR TREATING CANCERS | Gilead Sciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016010862-A1 | COMBINATIONS FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015109286-A1 | THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| EP-2579878-A1 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS | Gilead Calistoga LLC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030793-A1 | METHODS AND COMPOSITIONS FOR TREATING CD33+ CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS | HAVCR2, CD2, CD4 | PDE7A 398/4885PDE4D 2062/4885PDE4A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.